[Role of anti-angiogenic factor chondromodulin-I for maintaining cardiac valvular function]

Area of Science:

• Cardiovascular Biology
• Angiogenesis Research
• Molecular Cardiology

Background:

• Cardiac valves are typically avascular tissues, crucial for heart function.
• Dysregulation of vascularization in valves is linked to valvular heart diseases.
• Chondromodulin-I is a newly identified anti-angiogenic factor in valvular tissue.

Purpose of the Study:

• To investigate the role of chondromodulin-I in maintaining cardiac valve avascularity.
• To determine the impact of chondromodulin-I deficiency on valvular health and disease development.
• To explore chondromodulin-I's therapeutic potential in preventing cardiac valve disease.

Main Methods:

• Expression analysis of chondromodulin-I during cardiac valve development and in disease models.
• In vitro studies using valvular interstitial cells and endothelial cells to assess anti-angiogenic effects.
• Gene targeting of chondromodulin-I in mice to evaluate its in vivo function.
• Echocardiography to assess cardiac valve structure and function in aged mice.

Main Results:

• Chondromodulin-I expression is restricted to cardiac valves from late embryogenesis onwards.
• Down-regulation of chondromodulin-I correlates with increased vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) expression and neovascularization in disease states.
• Chondromodulin-I inhibits endothelial cell tube formation and migration in vitro.
• Gene targeting of chondromodulin-I leads to neovascularization, lipid deposition, calcification, and aortic valve thickening in aged mice.

Conclusions:

• Chondromodulin-I is a critical endogenous factor that prevents angiogenesis in cardiac valves.
• Loss of chondromodulin-I promotes neovascularization and contributes to the pathogenesis of valvular heart diseases.
• Chondromodulin-I represents a potential therapeutic target for preventing or treating cardiac valve dysfunction.